Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib 60 mg versus 140 mg in progressive metastatic medullary thyroid cancer
NL-OMON47076Phase 4Active, not recruiting
- Sponsor
- Exelixis, Inc.
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of cabozantinib in Medullary Thyroid Cancer (MTC) and thyroid cancer, sponsored by Exelixis, Inc. Primary endpoint: Progression-free survival. Started Aug 2015; status: active, not recruiting.
02
Drugs
cabozantinib
03
Conditions
Medullary Thyroid Cancer (MTC)thyroid cancer
Beyond the preview
Go deeper on NL-OMON47076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47076.